Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.99 -0.19 (-0.15%)
Streaming Delayed Price Updated: 3:36 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
69 70 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
7 Healthcare Stocks to invest in for a Healthy Future ↗
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase ↗
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.  
Via Benzinga
News headline image
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock ↗
The companies are hoping to use antibody drug conjugates in lung cancer patients. 
Via Investor's Business Daily
News headline image
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? ↗
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! 
Via InvestorPlace
News headline image
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why ↗
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership. 
Via Benzinga
News headline image
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now ↗
These companies aren't getting the respect they deserve. 
Via The Motley Fool
News headline image
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
5 Reasons Gilead Sciences is a Better Buy Than You Think
Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next. 
Via MarketBeat
News headline image
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip ↗
Wall Street price targets suggest this stock can rocket more than 400% higher. 
Via The Motley Fool
News headline image
Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
News headline image
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps 
Via MarketBeat
Topics Economy Stocks
News headline image
Pharma Giants Combine Forces to Fight New M&A Rules ↗
Some of pharma's biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms. 
Via The Motley Fool
News headline image
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
News headline image
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Magnificent Dividend Stocks to Buy in October ↗
These stocks come with great dividends and more. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study ↗
Gilead Sciences Inc (NASDAQ: GILD) said it has  
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.